BDC-4182

Bolt Biotherapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	BDC-4182
Sponsor	Bolt Biotherapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BDC-4182 CI brief — competitive landscape report
BDC-4182 updates RSS · CI watch RSS
Bolt Biotherapeutics, Inc. portfolio CI